UT Health San Antonio MD Anderson Cancer Center | Strategic Alliance Partners

Latest from UT Health San Antonio MD Anderson Cancer Center


Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 06, 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

x